PALI:NASDAQ, Palisade Bio, Inc.
PALI stock overview
Palisade Bio, Inc. (PALI:NASDAQ) closed at $1.35 on October 22, 2026,
down 3.57% on the day.
The stock trades 52.8% below its 52-week high of $2.86
and 2.3% above its 52-week low of $1.32.
Over the past year, it lost 14.1%.
Palisade Bio, Inc. is part of the Health Care sector.
Key figures
- Price
- $1.35
- Day change
- -3.57%
- Volume
- 1,114,128
- Average volume
- 2,507,637
- Market cap
- 235M+
- 52-week range
- $1.32 – $2.86
- 50-day average
- $1.77
- 200-day average
- $1.88
Price action over the past year
In 252 trading sessions since October 22, 2025, PALI closed higher on 114 days (45%).
Its best day was June 29, 2026 (+17.99%) and its worst was April 22, 2026 (-16.43%).
The stock moved 10% or more in a single session 21 times.
It opened at least 5% above the previous day's high 2 times.
Recent signals
PALI news
-
Oct 20, 2026:
Palisade Bio Presents Rapid Endoscopic Improvement and New Translational Evidence for PALI-2108 in Inflammatory Bowel Disease at UEG Week 2026
-
Oct 12, 2026:
Palisade Bio Presents New Clinical, Pharmacokinetic, Pharmacodynamic and Mechanistic Data Strengthening the Phase 2 Rationale for PALI-2108 in Ulcerative Colitis and Crohn's Disease at ACG 2026
-
Sep 28, 2026:
Palisade Bio to Present Clinical and Translational Data for PALI-2108 in Ulcerative Colitis and Crohn's Disease at UEG Week 2026
-
Sep 27, 2026:
Palisade Bio Advances PALI-2108 Into Phase II for Ulcerative Colitis and Crohn's
-
Sep 23, 2026:
Palisade Bio Expands Global Phase 2b ASCENTRA-UC Program with Health Canada CTA Clearance
-
Sep 22, 2026:
Palisade Bio Receives FDA Clearance of IND for PALI-2108 in Crohn's Disease, Expanding Phase 2 Development Across IBD
-
Sep 21, 2026:
Palisade Bio to Present at Stifel 2026 Virtual Immunology and Inflammation Forum
-
Sep 3, 2026:
Palisade Bio to Participate in Upcoming Investor Conferences
About Palisade Bio, Inc.
Palisade Bio Inc is a late-stage biopharma company. It is advancing oral therapies that help patients with acute and chronic gastrointestinal complications stemming from post-operative digestive enzyme damage. Palisade Bio's innovative lead asset, LB1148, is a Phase 3-ready protease inhibitor with the potential to both reduce abdominal adhesions and help restore bowel function following surgery.
Similar stocks
Find more stocks like PALI with the
Spikes,
Gaps,
Breakouts and
Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.